Alnylam Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $19.26BP/E 7.5Yield –
Alnylam Pharmaceuticals Net Cash Provided by Operating Activities
Net Cash Provided by (Used in) Operating Activities ($M)
Alnylam Pharmaceuticals Net Cash Provided by Operating Activities: $341M in Q3 2026, up 14.9% from a year earlier.
Where the Q3 2026 figure comes from
Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)
Source: Alnylam Form 10-Q (filed 2026-10-29) ↗
Reported in Form 10-Q & Form 10-K Consolidated Statements of Cash Flows.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up net Cash Provided by Operating Activities
- Capital Expenditures (Purchases of Property, Plant & Equipment)-69.8 · Q3 2026
- Depreciation and Amortization14.5 · Q3 2026
- Stock-Based Compensation Expense79.1 · Q3 2026
- Net Cash Used in Investing Activities-312 · Q3 2026
- Net Cash Provided by Financing Activities18.4 · Q3 2026
- Cash Paid for Interest73.3 · Q3 2026
- Cash Paid for Income Taxes, Net of Refunds15.1 · Q3 2026
Cite this data
StockData. (2026). Alnylam Pharmaceuticals Net Cash Provided by Operating Activities ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Alnylam Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/alny/kpis/db-operating-cf
See every metric in the Alnylam Pharmaceuticals KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?